English | 简体中文 | 繁體中文 | 한국어
Share:
Nexstim Plc Signs Canadian Distribution Agreement for its SmartFocus(TM) TMS systems with Canadian Health Solutions CHS

Press release, Helsinki, 7 January 2019 at 1.00 pm EET

Nexstim Plc Signs Canadian Distribution Agreement for its SmartFocus(TM) TMS systems with Canadian Health Solutions CHS

Nexstim Plc (NXTMH:HEX, NXTMS:STO), the targeted neuromodulation company developing and marketing pioneering navigated personalised, non-invasive brain stimulation systems for the treatment of Major Depression Disorder (MDD), announces it has signed a distribution agreement with Canadian Health Solutions to bring its SmartFocus(TM) TMS system to the Canadian market. The system is expected to be launched in Canada in the next few months.

Dr. David Elias, CEO of Canadian Health Solutions CHS, commented: "An estimated 10 per cent of Canadians use health services for mood and anxiety disorders annually.  According to Statistics Canada, 1,330,510Canadians over the age of 15 reported indicators for 'Major depression episode' in 2012*. Canadian Health Solutions ispleasedto be the distributor for Nexstim's NBT® system, which is based on a unique transcranial magnetic stimulation (TMS) technology. Based upon our deep understanding and research into mental health issues, we believe Nexstim's system has great potential and could significantly benefit the large number of Canadians who are in need of improved treatment options for MDD."

Nexstim SmartFocusTM technology is differentiated by its sophisticated 3D navigation that uses its proprietary E-field algorithm to visualize the exact location, orientation and magnitude of the stimulation given to the brain to treat MDD.

Dr. David Elias continued: "Canadian Health Solutions has a successful record of development, implementation and delivery of tailored health solutions. Cost effectiveness and validated health outcomes are required for all our solutions. We are happy to partner with Nexstim in making TMS available to Canadians."

The distribution agreement covers both Nexstim's NBT® system for the treatment of MDD as well as the Nexstim NBS® system for presurgical mapping.

Martin Jamieson, Chairman and CEO of Nexstim Plc, said: "We are delighted to announce that we have signed an agreement with Canadian Health Solutions that has a long experience in implementing and delivering health solutions into the Canadian market. This agreement is an important step supporting our strategy to expand in North America, where we believe there is a significant commercial opportunity for our clearly differentiated NBT® system for the treatment of MDD. "

*2012 Canadian Community Health Survey https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1310046501  

***

Further information is available on the website www.nexstim.com or by contacting:

Nexstim 
Martin Jamieson, Chairman and CEO
+44 771 516 3942
[email protected]

Citigate Dewe Rogerson       
David Dible/Shabnam Bashir/ Sylvie Berrebi
+44 (0)207 2822949
[email protected]

About Nexstim Plc
Nexstim is a medical technology company focused on the development and commercialization of its world-leading SmartFocusTM TMS technology, a non-invasive brain stimulation system for the treatment of Major Depressive Disorder (MDD). The Company's proprietary Navigated Brain Therapy (NBT®) system, a highly sophisticated 3D navigation, is the only personalised, navigated transcranial magnetic stimulation (TMS) approach providing accurate targeting of the TMS to the specific area of the brain associated with MDD.

Nexstim's NBT® system has been launched in the US for the treatment of MDD following clearance from the FDA for marketing and commercial distribution for this indication. The NBT® system is CE marked in Europe for the treatment of major depression and chronic neuropathic pain.

In addition, Nexstim is commercialising its Navigated Brain Stimulation (NBS) system for diagnostic applications, based on the same technology. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden.

For more information please visit www.nexstim.com .

About Canadian Health Solutions CHS:www.canadianhealthsolutions.ca




This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Nexstim Oyj via Globenewswire

Copyright © Thomson Reuters 2019. All rights reserved.
Press Releases
AMG Advanced Metallurgical Group N.V. Announces Weekly Share Repurchase Program Transaction Details  
Apr 19, 2019 21:00 ET
SDLP - Seadrill Partners LLC receives early termination notice for the West Capricorn contract  
Apr 18, 2019 13:29 ET
CF&B Communication : Copenhagen May 16, 2019 - 30 listed companies, 40 institutional investors in One-to-One  
Apr 18, 2019 10:21 ET
Invitation to UPM's webcast and press conference on first quarter 2019 results  
Apr 18, 2019 09:00 ET
Nokia provides recast comparative segment results and additional financial disclosures for 2018 reflecting the new financial reporting structure  
Apr 18, 2019 08:01 ET
Lubrizol to Feature New Bio TPU Grades for 3D Printing and Molded Parts at Plastteknik Fair 2019  
Apr 17, 2019 22:59 ET
JCPenney Names New Principal Accounting Officer and Announces Key Strategic Executive Appointments  
Apr 17, 2019 19:59 ET
Lubrizol is Ready for ILSAC GF-6 - Announcing Lubrizol® PV1510 Additive Technology for the GF-6 Specification  
Apr 16, 2019 03:59 ET
JANET BAWCOM JOINS INGREDION AS GENERAL COUNSEL AND CORPORATE SECRETARY  
Apr 15, 2019 22:29 ET
Lubrizol Showcases Renewable-Sourced Estane® 3D ECO TPU for 3D Printing at RAPID + TCT 2019  
Apr 12, 2019 20:29 ET
More News >>
Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 5791 1818

Connect With us: